Calidi Biotherapeutics, Inc. (CLDI) earnings per share
Annual history
Fiscal years 2022 – 2025
USD / SHARE 4 PERIODS
| Period | End | Diluted | Filed |
|---|---|---|---|
| FY 2025 | 2025-12-31 | -$5.95 | 2026-03-27 |
| FY 2024 | 2024-12-31 | -$35.70 | 2025-03-31 |
| FY 2023 | 2023-12-31 | -$207.96 | 2024-03-15 |
| FY 2022 | 2022-12-31 | $358.80 | 2023-03-31 |
Quarterly history
Fiscal years 2022 – 2026
USD / SHARE 15 PERIODS
| Period | End | Diluted | Filed |
|---|---|---|---|
| Q1 2026 | 2026-03-31 | -$0.43 | 2026-05-14 |
| Q4 2025 | 2025-12-31 | $0.45 | 2026-03-27 |
| Q3 2025 | 2025-09-30 | -$2.21 | 2025-11-13 |
| Q2 2025 | 2025-06-30 | -$1.99 | 2025-08-08 |
| Q1 2025 | 2025-03-31 | -$2.21 | 2025-05-14 |
| Q4 2024 | 2024-12-31 | $6.70 | 2025-03-31 |
| Q3 2024 | 2024-09-30 | -$7.75 | 2024-11-12 |
| Q2 2024 | 2024-06-30 | -$16.75 | 2024-08-13 |
| Q1 2024 | 2024-03-31 | -$24.36 | 2024-05-14 |
| Q4 2023 | 2023-12-31 | $29.64 | 2024-03-15 |
| Q3 2023 | 2023-09-30 | -$16.92 | 2023-11-14 |
| Q2 2023 | 2023-06-30 | -$170.88 | 2023-08-21 |
| Q1 2023 | 2023-03-31 | -$90.00 | 2023-05-15 |
| Q4 2022 | 2022-12-31 | $608.40 | 2023-03-31 |
| Q3 2022 | 2022-09-30 | -$75.60 | 2022-11-14 |
Methodology
Annual rows come from the filer's 10-K and Q1–Q3 rows from the matching 10-Q; Q4 is derived as full-year minus nine-month YTD because XBRL doesn't tag Q4 as its own period. EPS Basic and EPS Diluted are reported directly by the filer. Per-share values are split-adjusted to the current share count (2 split s since 2024).
For the exact XBRL concepts and formulas, see the methodology reference for EPS, FCF per share, the Q4 derivation, and split adjustment.
CLDI CIK 0001855485 Source: EDGAR filings · all facts